220 related articles for article (PubMed ID: 20855462)
1. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.
Sun T; Lee GS; Oh WK; Pomerantz M; Yang M; Xie W; Freedman ML; Kantoff PW
Clin Cancer Res; 2010 Nov; 16(21):5244-51. PubMed ID: 20855462
[TBL] [Abstract][Full Text] [Related]
2. Genetic association of single nucleotide polymorphisms in P53 pathway with gastric cancer risk in a Chinese Han population.
Wu GC; Zhang ZT
Med Oncol; 2015 Jan; 32(1):401. PubMed ID: 25479941
[TBL] [Abstract][Full Text] [Related]
3. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.
Fang S; Krahe R; Lozano G; Han Y; Chen W; Post SM; Zhang B; Wilson CD; Bachinski LL; Strong LC; Amos CI
PLoS One; 2010 May; 5(5):e10813. PubMed ID: 20520810
[TBL] [Abstract][Full Text] [Related]
4. Maternal SNPs in the p53 pathway: risk factors for trisomy 21?
Boquett JA; Brandalize AP; Fraga LR; Schuler-Faccini L
Dis Markers; 2013; 34(1):41-9. PubMed ID: 23089923
[TBL] [Abstract][Full Text] [Related]
5. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
6. MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk.
Gansmo LB; Romundstad P; Birkeland E; Hveem K; Vatten L; Knappskog S; Lønning PE
Cancer Med; 2015 Dec; 4(12):1901-7. PubMed ID: 26471763
[TBL] [Abstract][Full Text] [Related]
7. Lack of association of the TP53 Arg72Pro SNP and the MDM2 SNP309 with systemic lupus erythematosus in Caucasian, African American, and Asian children and adults.
Onel KB; Huo D; Hastings D; Fryer-Biggs J; Crow MK; Onel K
Lupus; 2009 Jan; 18(1):61-6. PubMed ID: 19074170
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis.
Gansmo LB; Lie BA; Mæhlen MT; Vatten L; Romundstad P; Hveem K; Lønning PE; Knappskog S
Gene; 2021 Aug; 793():145747. PubMed ID: 34077778
[TBL] [Abstract][Full Text] [Related]
9. A role of HAUSP in tumor suppression in a human colon carcinoma xenograft model.
Becker K; Marchenko ND; Palacios G; Moll UM
Cell Cycle; 2008 May; 7(9):1205-13. PubMed ID: 18418047
[TBL] [Abstract][Full Text] [Related]
10. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort.
Sun T; Mary LG; Oh WK; Freedman ML; Pomerantz M; Pienta KJ; Kantoff PW
Clin Cancer Res; 2011 Mar; 17(6):1546-52. PubMed ID: 21135144
[TBL] [Abstract][Full Text] [Related]
11. A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer.
Kulkarni DA; Vazquez A; Haffty BG; Bandera EV; Hu W; Sun YY; Toppmeyer DL; Levine AJ; Hirshfield KM
Carcinogenesis; 2009 Nov; 30(11):1910-5. PubMed ID: 19762336
[TBL] [Abstract][Full Text] [Related]
12. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.
Ebid GT; Sedhom IA; El-Gammal MM; Moneer MM
Asian Pac J Cancer Prev; 2012; 13(9):4315-20. PubMed ID: 23167335
[TBL] [Abstract][Full Text] [Related]
13. Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression.
Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Herrera-Ramos E; Rodríguez-Gallego C; Rodríguez-Melcón JI; Lara PC
BMC Med Genet; 2014 Dec; 15():143. PubMed ID: 25540025
[TBL] [Abstract][Full Text] [Related]
14. A dynamic role of HAUSP in the p53-Mdm2 pathway.
Li M; Brooks CL; Kon N; Gu W
Mol Cell; 2004 Mar; 13(6):879-86. PubMed ID: 15053880
[TBL] [Abstract][Full Text] [Related]
15. MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer.
Xue L; Han X; Liu R; Wang Z; Li H; Chen Q; Zhang P; Wang Z; Chong T
Oncotarget; 2016 May; 7(22):31825-31. PubMed ID: 26025918
[TBL] [Abstract][Full Text] [Related]
16. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
17. Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility.
Liu J; Tang X; Li M; Lu C; Shi J; Zhou L; Yuan Q; Yang M
Breast Cancer Res Treat; 2013 Jul; 140(1):151-7. PubMed ID: 23793604
[TBL] [Abstract][Full Text] [Related]
18. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
19. P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype.
Rogler A; Rogenhofer M; Borchardt A; Lunz JC; Knoell A; Hofstaedter F; Tannapfel A; Wieland W; Hartmann A; Stoehr R
Pathobiology; 2011; 78(4):193-200. PubMed ID: 21778786
[TBL] [Abstract][Full Text] [Related]
20. Germline genetics of the p53 pathway affect longevity in a gender specific manner.
Groß S; Immel UD; Klintschar M; Bartel F
Curr Aging Sci; 2014; 7(2):91-100. PubMed ID: 24654968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
